Not a good buy right now: price is weak (below pivot) and momentum remains bearish despite being near support.
Options positioning looks bullish (low put/call ratios) and a short-term bounce is possible, but insider selling is a clear negative overhang.
With earnings on 2026-02-19 (after hours), risk/reward is not attractive for an impatient entry without a confirmed trend reversal.
Technical Analysis
Current price $50.36 is sitting just above S1 support (50.052); next support S2 is 47.277 if S1 breaks.
Pivot/resistance is much higher at 54.545; price is below this level, so trend control is still with sellers.
MACD histogram is negative (-0.43) but contracting: downside momentum is slowing, yet not reversed.
RSI(6) ~38: leaning weak/near-oversold, consistent with a potential bounce but not a strong buy signal.
Moving averages are converging: suggests a transition phase, but no confirmed uptrend yet.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Put/Call ratios are low (OI PCR 0.54; Volume PCR 0.28), indicating bullish-to-risk-on positioning versus protective put demand.
IV is relatively subdued: 30D IV ~57.24 vs HV ~60.04; IV percentile 14.34 (low), suggesting options are not pricing extreme fear.
Today’s option volume is elevated vs its 30-day average (3.96x), indicating increased attention/positioning around current levels.
Net read: sentiment in options skew is constructive, but it’s not translating into a confirmed bullish price trend yet.
Technical Summary
Sell
10
Buy
3
Positive Catalysts
Near-term technical setup: price is sitting on/near first support (S1 ~50.05), where reflex bounces often occur.
Pipeline narrative remains a longer-term positive in news flow (multiple programs discussed; ongoing development updates).
Earnings catalyst ahead: QDEC 2025 earnings on 2026-02-19 after hours could re-rate the stock if Casgevy trajectory or pipeline updates improve.
Options market skew (low put/call) implies traders are leaning bullish rather than hedging aggressively.
Neutral/Negative Catalysts
with MACD below zero.
can create downside gaps if guidance or commercial metrics disappoint.
Financial Performance
Latest reported quarter: 2025/Q3.
Revenue rose to ~$0.889M (+47.67% YoY) off a small base.
Net income improved to -$106.441M (loss narrowed ~23.85% YoY improvement).
EPS improved to -1.17 (+15.84% YoY improvement), indicating losses are shrinking but profitability is still far.
Overall: improving loss profile, but the business is still dependent on execution (commercial ramp + pipeline progress).
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent sell-side stance is mostly constructive (Buy/Outperform/Overweight), but price targets have been repeatedly trimmed.
Examples: Citizens cut PT to $80 (Outperform); BofA trims to $89/$90 range (Buy); Chardan to $74 (Buy); Citi to $77 (Buy); JPMorgan to $69 (Overweight).
The more cautious camp remains present: Baird Neutral with PT $44; Clear Street Hold PT $50; RBC Sector Perform PT $50.
Wall Street ‘pros’ view: significant pipeline optionality not fully valued and potential for late-stage development over time.
Wall Street ‘cons’ view: near-term commercial/Casgevy ramp uncertainty and need for clearer inflection points in revenue and pipeline data.
Wall Street analysts forecast CRSP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRSP is 68.88 USD with a low forecast of 40 USD and a high forecast of 105 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
18 Analyst Rating
Wall Street analysts forecast CRSP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRSP is 68.88 USD with a low forecast of 40 USD and a high forecast of 105 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Buy
7 Hold
0 Sell
Moderate Buy
Current: 45.880
Low
40
Averages
68.88
High
105
Current: 45.880
Low
40
Averages
68.88
High
105
Citizens
Outperform
maintain
$86 -> $80
AI Analysis
2026-01-30
Reason
Citizens
Price Target
$86 -> $80
AI Analysis
2026-01-30
maintain
Outperform
Reason
Citizens lowered the firm's price target on Crispr Therapeutics to $80 from $86 and keeps an Outperform rating on the shares. Much of the pipeline opportunity is not valued at the moment and Crispr could initiate late-stage development in up to seven opportunities in 2027, the analyst tells investors in a research note.
BofA
Alec Stranahan
Buy
downgrade
$90 -> $89
2026-01-22
Reason
BofA
Alec Stranahan
Price Target
$90 -> $89
2026-01-22
downgrade
Buy
Reason
BofA analyst Alec Stranahan lowered the firm's price target on Crispr Therapeutics to $89 from $90 and keeps a Buy rating on the shares. The firm slightly reduced 2026 expectations for Casgevy, but still expects continued sequential growth in 2026, the analyst tells investors in an earnings preview for the group.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CRSP
